In Phase II clinical trials, tesofensine produced clear and measurable results in adults with obesity. In a 24-week randomized, double-blind, placebo-controlled study, participants who received tesofensine once daily at doses of 0.25 mg, 0.5 mg, and 1.0 mg experienced mean weight reductions of 4.5 percent, 9.2 percent, and 10.6 percent, respectively, compared with about 2.0 percent with diet and placebo alone. These results show a dose-dependent pattern of tesofensine weight loss.
Clinical analysis also found that tesofensine at 0.5 mg might produce approximately twice the mean weight reduction achieved by some approved anti-obesity medications over the same period.
Explore Tesofensine from My Peptides, a research compound studied for its effects on appetite regulation and body weight in clinical settings.
The process of tesofensine weight loss begins as the compound acts in the brain by blocking the presynaptic reuptake of the neurotransmitters dopamine, norepinephrine, and serotonin.
This triple monoamine reuptake inhibition increases the synaptic availability of these neurotransmitters, which centrally regulate appetite and feeding behavior. Tesofensine’s ability to inhibit these transporters serves as a defining feature of its mechanism of action.
Preclinical research in diet-induced obese rats shows that tesofensine induces a marked reduction in food intake, and a strong hypophagic response reflects this appetite suppression. In obese animal models, the indirect stimulation of noradrenergic and dopaminergic pathways in the central nervous system drives tesofensine’s appetite-suppressing effect, leading to reduced caloric intake and consequent weight reduction.
Discover AOD-9604 from My Peptides, a synthetic peptide investigated for its role in fat metabolism and lipolysis research.
Preclinical research in diet-induced obese rats shows that tesofensine blocks body weight rebound after prior treatment with 5-hydroxytryptophan. Investigators observed that tesofensine prolonged the reduction in body weight and prevented the rebound increase in body mass during the days following the withdrawal of the initial compound. Researchers documented sustained decreases in food intake during tesofensine administration, which contributed to continued weight reduction in the treated animals.
The same study showed that tesofensine maintained lower body weight compared with the control groups during the post-treatment observation period. These findings demonstrate that tesofensine prevents weight rebound in controlled animal models.
Beyond tesofensine weight loss research, researchers have evaluated peptides in clinical and preclinical studies for their effects on fat reduction and body composition.
While research on tesofensine focuses on central appetite pathways and body weight regulation, peptides target fat metabolism and visceral adiposity through different biological mechanisms.
Checkout Tesamorelin from My Peptides, a growth hormone–releasing hormone analogue studied for its impact on visceral adipose tissue.
AOD-9604 is a synthetic analogue of the lipolytic domain of human growth hormone, and researchers are investigating its effects on fat metabolism. In preclinical studies in obese rodents, AOD-9604 reduced body-weight gain and increased fat oxidation and lipolysis compared with control animals, indicating an enhanced breakdown of stored fat.
Investigators also reported that AOD-9604 increased beta-adrenergic receptor expression in adipose tissue, which correlated with fat breakdown activity in treated mice. Clinical research in humans did not demonstrate statistically significant weight loss in longer trials, and developers terminated AOD-9604 as an anti-obesity agent when later studies failed to show sufficient efficacy over placebo.
Published studies therefore show AOD-9604 supports fat breakdown and increased lipolysis in animal research, while human evidence on meaningful weight loss remains limited.
Clinical research consistently shows that tesamorelin reduces visceral adipose tissue (VAT) in adults with excess abdominal fat.
Randomized, double-blind, placebo-controlled trials found that daily tesamorelin treatment over 26 to 52 weeks produced significant decreases in VAT area compared with placebo in persons with HIV-associated abdominal adiposity. Patients treated with tesamorelin experienced larger reductions in visceral adipose tissue area versus those on placebo, with significant differences in VAT changes from baseline.
Several analyses report that tesamorelin decreases trunk fat and waist circumference along with VAT, and in many cases, it maintains VAT reduction through 52 weeks of treatment. Investigators also identify that a majority of patients treated with tesamorelin achieve clinically meaningful reductions in VAT (defined as a ≥ 8 percent decrease). These decreases in visceral adipose tissue occur without significant changes in subcutaneous fat, indicating a selective impact on belly fat.
Research on tesofensine weight loss demonstrates consistent, dose-related reductions in body weight and sustained appetite suppression in controlled studies. Clinical findings confirm meaningful weight reduction during active treatment, and preclinical data show continued effects on food intake and body weight regulation. These results position tesofensine as a compound with a measurable impact on obesity research.
Researchers expect future tesofensine weight loss studies to focus on larger clinical trials, long-term outcomes, and extended safety evaluation. Continued research may clarify its role in structured weight management strategies and determine how it compares with other centrally acting anti-obesity agents. Ongoing investigation provides a clear path for further development in obesity science.
[1] Nielsen AL, Larsen TM, Madsbad S, Breum L, et al. Effekt af tesofensine pÃ¥ kropsvaegt og kropssammensaetning hos svaert overvaegtige–sekundaerpublikation [The effect of tesofensine on body weight and body composition in obese subjects–secondary publication]. Ugeskr Laeger. 2009 Oct 5;171(41):2974-7.
[2] Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010 Jun;35(7):1464-76.
[3] Heffernan M, Summers RJ, Thorburn A, Ogru E, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9.
[4] Stanley TL, Falutz J, Marsolais C, Morin J, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51.
Does the FDA approve Tesofensine for obesity treatment?
Tesofensine does not have U.S. Food and Drug Administration approval for the treatment of obesity. Clinical studies have evaluated tesofensine in Phase II trials for weight reduction, but regulatory authorities have not granted marketing approval. Published clinical data continue to describe tesofensine as an investigational anti-obesity compound.
Does Tesofensine affect energy expenditure?
Tesofensine influences central neurotransmitters involved in energy balance. Clinical trials show that tesofensine reduces body weight primarily through decreased food intake. Published data do not report significant direct increases in resting energy expenditure in humans during treatment.
Is Tesofensine weight loss dose-dependent?
Clinical trials demonstrate a dose-dependent pattern in Tesofensine weight loss. Higher daily doses produced greater mean body weight reductions compared with lower doses and placebo over 24 weeks. Investigators reported statistically significant differences across dosing groups.
Does Tesofensine cause nausea or digestive issues?
Clinical trials report nausea, dry mouth, constipation, and insomnia during tesofensine treatment. Investigators observed these adverse effects more frequently at higher doses compared with placebo. Researchers reported that most gastrointestinal events were mild to moderate in severity.
Does Tesofensine boost metabolism?
Tesofensine blocks presynaptic reuptake of dopamine, norepinephrine, and serotonin, which influences appetite and body weight regulation. Clinical data attribute weight loss primarily to reduced caloric intake. Published studies do not confirm significant increases in metabolic rate as the main driver of weight reduction.
ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE INTENDED FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: All products sold by My Peptides are strictly intended for research and laboratory use only. These items are not designed for human or animal use or consumption. They are not classified as drugs, food, cosmetics, or medicinal products and must not be mislabeled or misused as such. By purchasing from our website, buyers acknowledge and accept all risks associated with handling these materials. The information and articles provided on this website are purely for educational and informational purposes. Handling and usage of these products should be carried out exclusively by qualified professionals.
PT-141 The Emerging Peptide Revolutionising Research The world of scientific research constantly pushes the limits of human understanding. Within this vast field, some discoveries attract more attention from scientists than others. One such discovery is the synthetic peptide known as PT-141, also called Bremelanotide, which researchers study for its effects
Exploring IGF-1 LR3 Peptide and Its Role in Scientific Research Biomedical researchers use recombinant proteins and peptides to push the boundaries of scientific discovery. Scientists actively study IGF-1 LR3, a synthetic analog of insulin-like growth factor-1, because it stimulates IGF-1 receptor signaling and supports cellular growth in experimental models. This
Understanding the BPC-157 and TB-500 Blend for Faster Recovery The body repairs damaged tissue through a coordinated sequence involving cell migration, vascular signaling and collagen restructuring. Researchers study a BPC-157 and TB-500 Blend because it allows examination of how these repair stages interact within the same experimental setting. This combined
Copyright 2025/26 - mypeptides.net
